We collaborate with national & international Doctors & Researchers around the world to help educate & provide research about #MOGAD. 501(c)3 🌺 #ViewsAreOurOwn
United States
Joined April 2020
- Tweets2.1K
- Following2K
- Followers2.4K
- Likes6.4K
Pinned Tweet
How does MOGAD affect daily life for children and families around the world?
The global IMPACT Survey invites young people ages 12–20 with MOGAD and parents/guardians of those ages 0–20 to share their experiences.
Anonymous. 20–30 min.
Take part: redcap.link/impact-survey
Sponsored by UCB.
Welcome Dr. Haiwen Chen to The MOG Project’s Medical & Scientific Advisory Council!
A pediatric neuroimmunologist at Johns Hopkins, Dr. Chen combines clinical MOGAD research with laboratory studies exploring how brain cells influence neuronal communication.
Meet Dr. Chen: mogproject.org/medical-advis…
#MOGAD
The MOG Project retweeted
🧠 Satralizumab (Enspryng) reduced relapse risk by 68% vs placebo in the phase 3 METEOROID trial in relapsing MOGAD
📊 At 48 weeks, 87.3% of patients receiving satralizumab remained relapse-free vs 66.5% with placebo
🔬 Findings from #CNS2026: hubs.li/Q04BpK2J0
#MOGAD #Neurology
New in @GreenJournal a study of 312 children with #MOGAD links IV immunoglobulin (#IVIG) to a 46% lower relapse risk. Observational, so trials are still needed. Congratulations @tweetsatakash and the whole team! 🩵
neurology.org/doi/10.1212/WN…
The MOG Project retweeted
Delighted to share our international review on MRI Characteristics of #MOGAD! ➡️ Key imaging features are highlighted across the brain, optic nerves & spinal cord including lesion dynamics ➡️ Illustrative figures help show its full imaging spectrum👇
jamanetwork.com/journals/jam…
The MOG Project retweeted
This retrospective cohort study with a preplanned analysis found that prednisolone ≥10 mg treatment for ≥3 months after the index event was associated with a lower likelihood of relapsing MOGAD: hubs.la/Q04w51LN0
The MOG Project retweeted
Children can develop the full spectrum of MOGAD-like encephalitis without MOG-IgG. Clinical features and immunotherapy response are similar to MOGAD, but relapses are uncommon: hubs.la/Q04vrm6_0
The MOG Project retweeted
Hacohen et al. review and assess the current evidence, make clinical considerations, and propose future directions for treatment de-escalation and discontinuation in MOGAD and AQP4-Ab NMOSD: hubs.la/Q04vs21q0
The MOG Project retweeted
Become an @ISNI_neuro member now to be eligible for travel awards to
join us in beautiful Venice. More update on the program soon. #WeAreNeuroimmunology
Make the most of your experience at the 18th International Congress of Neuroimmunology in Venice.
ISNI members enjoy:
• Reduced Congress registration rates
• Eligibility to apply for Travel Awards
• Early access to registration
Complimentary membership is available for all new and renewing members through the end of 2026, so you can start taking advantage of these benefits today.
🔗 Become a member: isniweb.org/become-a-member
#WeAreNeuroimmunology #Neuroimmunology #ISNICongress2027
The MOG Project retweeted
Nos vemos hoy! @NeuroinmunUC
🧠 ¿Cómo han cambiado las opciones terapéuticas para la NMOSD y el MOGAD en los últimos años?
La quinta sesión de NMOSD Focus Sessions reunirá a dos expertas internacionales para analizar los tratamientos inmunosupresores e inmunomoduladores disponibles y su aplicación en la práctica clínica.
📚 Tratamientos inmunosupresores / inmunomoduladores de la NMOSD y MOGAD
🎙️ Dra. Maria Sepúlveda – Neuróloga, Hospital Clínic de Barcelona (España)
🎙️ Dra. Ethel Ciampi – Neuróloga, Pontificia Universidad Católica de Chile, Hospital Sótero del Río (Chile)
Moderada por:
🔹 Dra. Georgina Arrambide – Neuróloga, Cemcat (Barcelona)
📅 Miércoles, 16 de septiembre de 2026
🕒 15:00–16:00 h (CEST)
🌐 Online | Español
🔗 Regístrate:
bit.ly/NMOSDFocusSessions202…
#NMOSD #MOGAD #Neuroinmunología #Neurología #MedicalEducation #CemcatEducation
The MOG Project retweeted
A step forward for MOGAD: FDA granted Priority Review to Enspryng® (satralizumab) — potentially the first MOGAD treatment. Trial: 68% lower relapse risk vs placebo. FDA decision expected Jan 10 2027.
gene.com/media/press-release…
The MOG Project retweeted
Antibody-associated disorders such MOGAD and NMOSD rely on antibody tests for their diagnosis, rendering accessibility to testing paramount to the care and treatment of people with MOGAD and NMOSD.
ISNI is pleased to support a worldwide survey on AQP4- and MOG-IgG testing accessibility and laboratory testing strategies with the aiming of mapping the current access to AQP4-IgG and MOG-IgG testing and to understand issues that limit testing access around the world.
Two surveys are available: one for neurologists who request testing and the other one for head scientists and immunopathologists who provide the testing.
Please consider spending 12 minutes to complete one of the surveys.
Learn more & access the survey here: isniweb.org/testing-survey
@FabienneBrilot , Paddy Waters, matteo gastaldi, @SaraMariottoMD and @hwiendl
#MOGantibodyTaskForce
The MOG Project retweeted
#AQP4 & #MOG antibody testing is paramount for #NMOSD & #MOGAD diagnosis.
Help us understand global accessibility @MGastaldi85 @TheMOGProject @TheSumairaFDN @syd_health @IntNatlWiMS @kids_research @amandajanelaing @westmeadkids @ECTRIMS @PACTRIMS_admin @ACTRIMS @MS_Australia
Antibody-associated disorders such MOGAD and NMOSD rely on antibody tests for their diagnosis, rendering accessibility to testing paramount to the care and treatment of people with MOGAD and NMOSD.
ISNI is pleased to support a worldwide survey on AQP4- and MOG-IgG testing accessibility and laboratory testing strategies with the aiming of mapping the current access to AQP4-IgG and MOG-IgG testing and to understand issues that limit testing access around the world.
Two surveys are available: one for neurologists who request testing and the other one for head scientists and immunopathologists who provide the testing.
Please consider spending 12 minutes to complete one of the surveys.
Learn more & access the survey here: isniweb.org/testing-survey
@FabienneBrilot , Paddy Waters, matteo gastaldi, @SaraMariottoMD and @hwiendl
#MOGantibodyTaskForce
A step forward for MOGAD: FDA granted Priority Review to Enspryng® (satralizumab) — potentially the first MOGAD treatment. Trial: 68% lower relapse risk vs placebo. FDA decision expected Jan 10 2027.
gene.com/media/press-release…
The MOG Project retweeted
NEW results from our 2nd Propulsion Survey on life after a #MOGAD diagnosis are published in Neurology and Therapy. 261 patients/caregivers, 27 countries. Caregivers report far higher mental health impact than patients (92% vs 26%). doi.org/10.1007/s40120-026-0…
@Drjonsantoro @wearesrna @UCBUSA @JustJen_K
The MOG Project retweeted
#MOGAD US patient Summit 2026 you did not disappoint. Hot topics, research, patient perspectives, treatments, pregnancy, disease management & more with colleagues/friends near & far! All the way from Aus 🇦🇺🇺🇸👁️🧠🧬
@TheMOGProject @mlevy18 @ESotirchos Brenda Banwell @MyMyelitis – at Baltimore, MD
🤖 Made with AI
The MOG Project retweeted
Dr Brenda Banwell, an outstanding neurologist and an all time beautiful person discussing all things #MOGAD!
#MOGADUSSummit2026 @TheMOGProject @BrendaBanwell
NEW results from our 2nd Propulsion Survey on life after a #MOGAD diagnosis are published in Neurology and Therapy. 261 patients/caregivers, 27 countries. Caregivers report far higher mental health impact than patients (92% vs 26%). doi.org/10.1007/s40120-026-0…
@Drjonsantoro @wearesrna @UCBUSA @JustJen_K
The MOG Project retweeted
Acute treatment in MOGAD
should be viewed as a disease-modifying intervention, where early, timely, and appropriately escalated therapy has the potential to alter long-term outcomes ! tandfonline.com/doi/full/10.… @EoinFlanagan14 @NeuroinmunUC @TheMOGProject
